HORIZON THERAPEUTICS PLC (HZNP) Stock Price, Forecast & Analysis
USA - NASDAQ:HZNP - IE00BQPVQZ61 - Common Stock
HZNP Key Statistics, Chart & Performance
The current stock price of HZNP is 116.3 USD. In the past month the price increased by 0.77%. In the past year, price increased by 78.92%.
HZNP Latest News, Press Relases and Analysis
HZNP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.43 | 374.44B | ||
| AMGN | AMGEN INC | 13.59 | 159.52B | ||
| GILD | GILEAD SCIENCES INC | 14.9 | 151.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.54 | 109.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.27 | 68.07B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.12 | 56.90B | ||
| ARGX | ARGENX SE - ADR | 61.62 | 50.87B | ||
| INSM | INSMED INC | N/A | 39.36B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.04 | 34.25B | ||
| NTRA | NATERA INC | N/A | 27.21B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.99B | ||
| BIIB | BIOGEN INC | 9.05 | 22.20B |
Related stock screener links
About HZNP
Company Profile
Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 2,190 full-time employees. The company went IPO on 2010-08-11. The firm is focused on the discovery, development and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases. The Company’s portfolio of medicines include ACTIMMUNE, BUPHENYL (sodium phenylbutyrate), KRYSTEXXA pegloticase, PROCYSBI (cysteamine bitartrate), Prescription RAVICTI (glycerol phenylbutyrate), TEPEZZA teprotumumab-trbw and other. ACTIMMUNE is part of a drug regimen used to treat Chronic Granulomatous Disease (CGD). BUPHENYL (sodium phenylbutyrate) is a tablet for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contains sodium phenylbutyrate. PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a prescription medicine used to treat nephropathic cystinosis in adults and children 1 year of age and older.
Company Info
HORIZON THERAPEUTICS PLC
70 St. Stephen's Green, Saint Kevin's, Dublin 2
DUBLIN DUBLIN D04 C5Y6 IE
CEO: Timothy Walbert
Employees: 2190
Phone: 35317722100.0
HORIZON THERAPEUTICS PLC / HZNP FAQ
What does HZNP do?
Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 2,190 full-time employees. The company went IPO on 2010-08-11. The firm is focused on the discovery, development and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases. The Company’s portfolio of medicines include ACTIMMUNE, BUPHENYL (sodium phenylbutyrate), KRYSTEXXA pegloticase, PROCYSBI (cysteamine bitartrate), Prescription RAVICTI (glycerol phenylbutyrate), TEPEZZA teprotumumab-trbw and other. ACTIMMUNE is part of a drug regimen used to treat Chronic Granulomatous Disease (CGD). BUPHENYL (sodium phenylbutyrate) is a tablet for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contains sodium phenylbutyrate. PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a prescription medicine used to treat nephropathic cystinosis in adults and children 1 year of age and older.
What is the stock price of HORIZON THERAPEUTICS PLC today?
The current stock price of HZNP is 116.3 USD. The price increased by 0.04% in the last trading session.
Does HORIZON THERAPEUTICS PLC pay dividends?
HZNP does not pay a dividend.
How is the ChartMill rating for HORIZON THERAPEUTICS PLC?
HZNP has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the number of employees for HORIZON THERAPEUTICS PLC?
HORIZON THERAPEUTICS PLC (HZNP) currently has 2190 employees.
What is the market capitalization of HZNP stock?
HORIZON THERAPEUTICS PLC (HZNP) has a market capitalization of 26.63B USD. This makes HZNP a Large Cap stock.
Can you provide the ownership details for HZNP stock?
You can find the ownership structure of HORIZON THERAPEUTICS PLC (HZNP) on the Ownership tab.
HZNP Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to HZNP. When comparing the yearly performance of all stocks, HZNP is one of the better performing stocks in the market, outperforming 96.67% of all stocks.
HZNP Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to HZNP. HZNP gets an excellent profitability rating and is at the same time showing great financial health properties.
HZNP Financial Highlights
Over the last trailing twelve months HZNP reported a non-GAAP Earnings per Share(EPS) of 4.49. The EPS decreased by -19.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.02% | ||
| ROA | 4.71% | ||
| ROE | 8.25% | ||
| Debt/Equity | 0.48 |
HZNP Forecast & Estimates
11 analysts have analysed HZNP and the average price target is 118.83 USD. This implies a price increase of 2.18% is expected in the next year compared to the current price of 116.3.
For the next year, analysts expect an EPS growth of -5.01% and a revenue growth 5.55% for HZNP